Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Gastroenterology · Myotonic Dystrophy Type 1

Does Myotonic Dystrophy Type 1 Cause GI Symptoms?

At a Glance

Myotonic dystrophy type 1 (DM1) frequently causes severe gastrointestinal issues because it weakens the smooth involuntary muscles and nerves of the digestive tract. Common symptoms include swallowing difficulties, gastroparesis, and severe constipation, which require multidisciplinary management.

Yes, myotonic dystrophy type 1 (DM1) can absolutely cause stomach issues, swallowing problems, and severe constipation. While DM1 is primarily known for affecting the skeletal muscles (the muscles you consciously control), it also affects the smooth muscles—the involuntary muscles that line your digestive tract [1][2]. In addition to the muscles themselves, the disease can damage the enteric nervous system (the nerves controlling your gut) [2][3]. This combination of muscle weakness and nerve dysfunction leads to a condition called gastrointestinal dysmotility, meaning food and waste do not move through your digestive system as efficiently as they should.

Although lower gastrointestinal symptoms (like constipation) do not appear to directly impact overall survival rates [4], they are highly common and can significantly affect your daily quality of life [5]. However, upper gastrointestinal issues like swallowing difficulties carry serious, life-threatening risks, such as aspiration pneumonia [6]. Because DM1 is a multisystemic disorder, managing these digestive symptoms requires a coordinated, multidisciplinary approach [7][8].

Common Digestive Symptoms in DM1

The digestive issues in DM1 can occur anywhere from the mouth to the large intestine. The most frequently reported problems include:

  • Dysphagia (Swallowing Difficulties): Weakness in the throat and mouth muscles makes oropharyngeal dysphagia a prominent feature of DM1 [6]. This can cause choking, coughing while eating, or a feeling that food is stuck, which increases the risk of inhaling food or liquid into the lungs (aspiration).
  • Delayed Gastric Emptying (Gastroparesis): Because the stomach muscles are weak, food sits in the stomach longer than normal [9]. This can cause you to feel full very quickly after eating only a small amount, and may lead to nausea, bloating, or vomiting.
  • Gallbladder Issues: Poor muscle motility can also affect how well the gallbladder empties, potentially increasing the risk of developing gallstones (cholelithiasis) or gallbladder disease [10][4]. (Note: If surgery is required for gallbladder issues, it is crucial to discuss anesthesia risks, as DM1 patients carry significant risks with general anesthesia [11][12].)
  • Severe Constipation and Pseudo-Obstruction: Slow movement through the intestines is one of the most common complaints [5]. In severe cases, it can lead to pseudo-obstruction, a serious condition where the bowel acts as if there is a physical blockage, even though none exists [13][14].
    • Emergency Warning (Red Flags): If you experience sudden, severe abdominal swelling (distension), an absolute inability to pass gas or stool, or intractable vomiting, go to the emergency room immediately. These are signs of pseudo-obstruction that require urgent medical care.

Management and Lifestyle Adjustments

While there is no cure for the underlying muscle weakness, many treatments can help manage these GI symptoms and improve your comfort [15][16]. Your care team will likely recommend a combination of therapies:

  • Swallowing Assessments and Speech Therapy: A multidimensional swallowing assessment is highly recommended for patients with DM1 [17]. This typically involves questionnaires (like the SWAL-QOL) and objective tests like a videofluoroscopic swallowing study (VFSS), where an X-ray records you swallowing food mixed with barium [6][17]. A speech-language pathologist can then teach you safer swallowing techniques or recommend modifying your food texture (e.g., using liquid thickeners, avoiding dry/crumbly foods, or eating pureed meals) to prevent choking [18][19].
  • Dietary Modifications: Managing nutrition can be complex because different parts of your gut may need conflicting dietary strategies. For instance, gastroparesis often improves with low-fiber, low-fat, small frequent meals, whereas constipation typically requires adequate fiber and high hydration. A registered dietitian who understands neuromuscular diseases can help you tailor your diet to balance these conflicting needs [7].
  • Medications: Your doctor may prescribe motility medications (prokinetics) to help stimulate muscle contractions in your stomach and intestines. Laxatives and stool softeners are also standard treatments for chronic constipation [13]. However, avoid relying heavily on over-the-counter stimulant laxatives without consulting your neuromuscular team, as chronic use can further damage gut motility. Furthermore, always discuss new medications with your team, as certain motility drugs may interfere with heart rhythms (a known risk in DM1), and other medications like sedatives can further slow down digestion [20][15].
  • Multidisciplinary Care: Managing DM1-related GI issues is complex, and you should ideally be supported by a team that includes a gastroenterologist, a neuromuscular specialist, a speech therapist, and a dietitian [15][13].

Common questions in this guide

Why does myotonic dystrophy type 1 cause stomach and digestive problems?
DM1 affects the smooth, involuntary muscles that line your digestive tract and can damage the nerves controlling your gut. This combination of muscle weakness and nerve damage prevents food and waste from moving efficiently, leading to gastrointestinal dysmotility.
What are the signs of a severe bowel blockage or pseudo-obstruction?
Warning signs of a pseudo-obstruction include sudden and severe abdominal swelling, an absolute inability to pass gas or stool, and uncontrollable vomiting. If you experience these red flag symptoms, you should go to the emergency room immediately.
How can I manage swallowing difficulties caused by DM1?
A speech-language pathologist can perform a swallowing assessment to recommend safe techniques and food modifications. This might include using liquid thickeners, avoiding dry foods, or switching to pureed meals to prevent choking and aspiration.
What should I eat to help with DM1 gastrointestinal symptoms?
Managing nutrition can be complex because gastroparesis often requires low-fiber, small frequent meals, while constipation requires adequate fiber and hydration. A registered dietitian who understands neuromuscular diseases can help you balance these conflicting needs.
Are there risks to using laxatives for constipation in DM1?
While laxatives and stool softeners are standard treatments, you should avoid relying heavily on over-the-counter stimulant laxatives without consulting your doctor. Chronic use of stimulants can further damage your gut motility over time.

Questions for Your Doctor

5 questions

  • Could you refer me to a speech-language pathologist to evaluate my swallowing safety using a videofluoroscopic swallowing study (VFSS)?
  • Which of my current medications might be making my slow digestion worse, and are there safe alternatives?
  • Given my potential risk for heart rhythm issues, which motility medications are safest for my constipation or early fullness?
  • How frequently should we monitor my gallbladder function given my risk for gallstones?
  • What specific 'red flag' symptoms should prompt me to go straight to the emergency room for a potential bowel pseudo-obstruction?

Questions for You

4 questions

  • Do you frequently cough, clear your throat, or feel like food is stuck when you eat or drink?
  • Have you noticed feeling unusually full or nauseous after eating small portions of food?
  • How often do you have bowel movements, and do you frequently experience painful bloating or severe abdominal cramps?
  • Are you currently taking any over-the-counter laxatives, supplements, or medications for digestion that your primary care team is unaware of?

References

References (20)
  1. 1

    Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.

    Sharp L, Cox DC, Cooper TA

    Muscle & nerve 2019; (60(6)):779-789 doi:10.1002/mus.26709.

    PMID: 31509256
  2. 2

    Precise small-molecule recognition of a toxic CUG RNA repeat expansion.

    Rzuczek SG, Colgan LA, Nakai Y, et al.

    Nature chemical biology 2017; (13(2)):188-193 doi:10.1038/nchembio.2251.

    PMID: 27941760
  3. 3

    Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy.

    Thomas JD, Sznajder ŁJ, Bardhi O, et al.

    Genes & development 2017; (31(11)):1122-1133 doi:10.1101/gad.300590.117.

    PMID: 28698297
  4. 4

    Survival in myotonic dystrophy type 1: a long time follow up-study with special reference to gastrointestinal symptoms.

    Rönnblom A, Ekbom A

    Upsala journal of medical sciences 2024; (129()) doi:10.48101/ujms.v129.10663.

    PMID: 39376588
  5. 5

    Impact of gastrointestinal and urological symptoms in children with myotonic dystrophy type 1.

    Maagdenberg SJM, Klinkenberg S, Sophie van den Berg J, et al.

    Neuromuscular disorders : NMD 2024; (35()):1-7 doi:10.1016/j.nmd.2023.12.011.

    PMID: 38184901
  6. 6

    Oropharyngeal dysphagia in early stages of myotonic dystrophy type 1.

    Franco-Guerrero AA, Márquez-Quiroz LC, Valadéz-Jiménez VM, et al.

    Muscle & nerve 2019; (60(1)):90-95 doi:10.1002/mus.26485.

    PMID: 30994189
  7. 7

    Myotonic Dystrophy.

    Perez PG

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1437-1461 doi:10.1212/cont.0000000000001621.

    PMID: 41037177
  8. 8

    Predictors of participation restriction over a 9-year period in adults with myotonic dystrophy type 1.

    Raymond K, Levasseur M, Gallais B, et al.

    Disability and rehabilitation 2022; (44(12)):2615-2631 doi:10.1080/09638288.2020.1837264.

    PMID: 33135946
  9. 9

    [Multiorgan manifestations in myotonic dystrophy type 1].

    Varga D, Pál E

    Orvosi hetilap 2019; (160(37)):1447-1454 doi:10.1556/650.2019.31505.

    PMID: 31495190
  10. 10

    High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

    Hilbert JE, Barohn RJ, Clemens PR, et al.

    Neurology 2017; (89(13)):1348-1354 doi:10.1212/WNL.0000000000004420.

    PMID: 28855409
  11. 11

    Cardiac Pathology in Myotonic Dystrophy Type 1.

    Mahadevan MS, Yadava RS, Mandal M

    International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111874.

    PMID: 34769305
  12. 12

    Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry.

    Chong-Nguyen C, Wahbi K, Algalarrondo V, et al.

    Circulation. Cardiovascular genetics 2017; (10(3)) doi:10.1161/CIRCGENETICS.116.001526.

    PMID: 28611030
  13. 13

    Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease.

    Gutiérrez Gutiérrez G, Díaz-Manera J, Almendrote M, et al.

    Neurologia 2020; (35(3)):185-206 doi:10.1016/j.nrl.2019.01.001.

    PMID: 31003788
  14. 14

    Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease.

    Gutiérrez Gutiérrez G, Díaz-Manera J, Almendrote M, et al.

    Medicina clinica 2019; (153(2)):82.e1-82.e17 doi:10.1016/j.medcli.2018.10.028.

    PMID: 30685181
  15. 15

    A Greek National Cross-Sectional Study on Myotonic Dystrophies.

    Papadimas GK, Papadopoulos C, Kekou K, et al.

    International journal of molecular sciences 2022; (23(24)) doi:10.3390/ijms232415507.

    PMID: 36555146
  16. 16

    Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.

    Okkersen K, Jimenez-Moreno C, Wenninger S, et al.

    The Lancet. Neurology 2018; (17(8)):671-680 doi:10.1016/S1474-4422(18)30203-5.

    PMID: 29934199
  17. 17

    Swallow-related quality of life and oropharyngeal dysphagia in myotonic dystrophy.

    Pilz W, Passos VL, Verdonschot RJ, et al.

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2020; (277(8)):2357-2362 doi:10.1007/s00405-020-05964-2.

    PMID: 32296979
  18. 18

    Myotonic Dystrophy.

    Hamel JI

    Continuum (Minneapolis, Minn.) 2022; (28(6)):1715-1734 doi:10.1212/CON.0000000000001184.

    PMID: 36537977
  19. 19

    Multiple Case Study of Changes in Participation of Adults with Myotonic Dystrophy Type 1: Importance of Redesigning Accomplishment and Resilience.

    Raymond K, Gagnon C, Levasseur M

    Journal of neuromuscular diseases 2022; (9(6)):731-755 doi:10.3233/JND-210780.

    PMID: 36214003
  20. 20

    Comprehensive Cardiovascular Management of Myotonic Dystrophy Type 1 Patients: A Report from the Italian Neuro-Cardiology Network.

    Russo V, Antonini G, Massa R, et al.

    Journal of cardiovascular development and disease 2024; (11(2)) doi:10.3390/jcdd11020063.

    PMID: 38392277

This page provides educational information about managing digestive symptoms in Myotonic Dystrophy Type 1. It does not replace professional medical advice, and you should always consult your gastroenterologist or neuromuscular specialist regarding your specific symptoms.

Get notified when new evidence is published on Steinert myotonic dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.